Introduction {#sec1}
============

The NMDA (*N*-methyl-[d]{.smallcaps}-aspartate) receptor is a ligand-gated ion channel, which reacts to binding of the amino acids [l]{.smallcaps}-glycine, [l]{.smallcaps}-glutamate, and NMDA. NMDA receptors are comprised of eight different NR1 subunits and four different NR2 subunits (A--D). The actual ion channels are tetramers constituted of two NR1 and two NR2 subunits, leading to distinct varieties of NMDA receptors.^[@ref1]^ The various subtypes have different expression patterns in the central nervous system. Brain regions rich in NR2B subunits are found in the cerebral cortex and hippocampus.^[@ref2]−[@ref4]^ By allowing influx of Ca^2+^, K^+^, and similar cations, NR2B mediates essential excitatory neurotransmission in healthy tissue, which may be altered in conditions such as schizophrenia. Inhibition of the receptor protects against the abnormal excitation of neurons implied in neurodegenerative diseases. Because of the potential relevance as target for the clinical management of neurodegenerative diseases, there is a profound need for suitable NR2B radioligands in the brain imaging community.^[@ref5],[@ref6]^ In addition, among NMDA ligands, NR2B selective antagonists have the advantage of being significantly less susceptible to impair locomotion in subjects compared to other NMDA subunit selective ligands.^[@ref7]^ We became interested in the receptor primarily for positron emission tomography (PET) imaging because of the role attributed to NMDA receptors in mechanisms leading to brain damage, for example, in stroke, hypoglycaemia, and dementia. Several ligands with promising in vitro properties have been developed; however, their translational development into PET radiotracers has not yet been entirely successful. Some evaluated candidates fail to penetrate the blood brain barrier,^[@ref8],[@ref9]^ others are metabolized too rapidly,^[@ref10],[@ref11]^ and the majority has shown selectivity issues^[@ref5],[@ref12]−[@ref17]^ often with high affinity to σ-receptors. Following thorough screening of the literature, we selected 1-(4-chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol, Ro 04--5595 (**1**) as the lead for the development of new radioligands. Compound **1** is described as an NR2B antagonist with selectivity over NR1 and NR2A receptor subtypes and a reported *K*~d~ estimate of 20 ± 3 nM from competitive binding studies.^[@ref2],[@ref18],[@ref19]^

Results and Discussion {#sec2}
======================

A library was designed to study the influence of methylation on the guaiacol ring, conformational restriction on the ethylene bridge, and substitution of the Cl-atom by fluorinated derivatives on binding ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Contrary to multistep Bischler--Napieralski reaction-based strategies methodological, structural variation became possible in a single step by condensing readily available phenethyl amines with substituted cinnamic aldehydes.^[@ref20]^ Pictet--Spengler cyclization reactions produced modest to good yields (24--83%) using **2a** for all cinnamic aldehydes; however, **2b** only afforded practically useful yields using *p-*NO~2~-cinnamic aldehyde (59%). *p-*Cl-cinnamic aldehyde produced 8%, which was sufficient for precursor synthesis (**4f**) ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)). [N]{.ul}-methylation of **4a-4g** was conveniently accomplished with formaldehyde and sodium triacetoxyborohydride. Catalytic hydrogenation was performed using Raney nickel instead of palladium on charcoal, which partially dechlorinated **5b**. Anilines (**5g** and **5h**) were converted into their corresponding chloride via a Sandmeyer reaction using sodium nitrite and copper(I) chloride.

![General Synthetic Strategy^a^\
(a) (i) EtOH, 35 °C, reduced pressure and (ii) TFA, 120 °C, mw; (b) (i) H~2~CO, DCE and (ii) Na(OAc)~3~BH; (c) Raney nickel, H~2~, MeOH/AcOH; (d) Raney Ni, H~2~, MeOH; (e) (i) NaNO~2~, HCl, H~2~O and (ii) CuCl in HCl.](ao-2019-00357c_0004){#sch1}

We initially evaluated the compounds (**1**, **4a-4g, 5a--5i, 6a-6f**) via preliminary screening wherein the synthesized ligands were evaluated by how well they displaced \[^3^H\]ifenprodil (\[^3^H\]**7**) on rat brain sections ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)). Ifenprodil is structurally very similar to both eliprodil and Ro 25-6981 but different from **1** and therefore a suitable ligand for studying binding displacement.

The competitive binding data was validated via autoradiography using \[^3^H\]**7** (27 nM) and **1** at seven concentrations to obtain an estimate of IC~50~ = 5 ± 10 nM (*K*~i~ = 2 ± 4 nM). The experiment had a larger uncertainty but was deemed sufficient for the preliminary screening. The relatively large uncertainty is explained by a low signal-to-noise ratio coming from residual nonspecific binding of \[^3^H\]**7.** Wiping experiments showed that 16% displacement of the total binding of \[^3^H\]**7** (27 nM) could be attributed to NR2B binding using **1** at 1 μM. The most promising derivatives were further evaluated via autoradiography at 1 and 10 μM where the displacement of \[^3^H\]**7** in both hippocampus (NR2B specific binding) and cerebellum (non-NR2B binding) was evaluated ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)).

Conformationally constrained, (*E*)-configured derivatives **1**, **5a**−**f** obtained via introduction of a double bond into the structure displayed lower potency than their freely rotable counterparts **6a**−**f**.^[@ref26]^ Substitution of the chlorine atom by fluoro or trifluoromethyl substituents did lead to potent inhibitors of \[^3^H\]**7** binding; however, none of the novel, fluorinated analogues in our library was found to be superior to **1.** Most compounds even displaced \[^3^H\]**7** in the cerebellum, which is devoid of NR2B receptors, indicating binding to other proteins.^[@ref21]^ To the contrary, **1** (1 μM) showed no displacement of \[^3^H\]**7** (27 nM) in the cerebellum but 23 ± 2% displacement in hippocampus. Therefore, we decided to subordinate the new compounds to **1** and continue with a thorough characterization of the ligand starting with PET.

To facilitate small animal PET studies in rats, 1-(4-chlorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol was synthesized and subjected to ^11^C-methylation with \[^11^C\]CH~3~I via the captive solvent method,^[@ref22]^ where the precursor was trapped on the HPLC injection loop and radioalkylated by passing \[^11^C\]MeI through the line. The PET radiotracer \[^11^C\]**1** was obtained in a yield of 13 ± 3% (compare with [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), a radiochemical purity (RCP) of 99% and a molar activity of 12--43 MBq/nmol. \[^11^C\]**1** was injected intravenously via the tail vein into anaesthetized (isofluorane), male Sprague--Dawley rats, 12--16 weeks, 380--420 g. One group was injected with no carrier added radioligand, and one rat was injected with carrier-added radioligand at a higher concentration (1 mg/kg). A 90 min dynamic PET scan was performed. For determination of metabolites in the blood and brain, \[^11^C\]**1** was administered to three further rats for metabolite studies. However, the remaining radioactivity after processing was too low to be useful for accurate determination of metabolites. We believe a likely reason is because of N-demethylation, which produces ^11^CO~2~ that diminishes the radioactive signal but is eliminated from the blood stream and subsequently exhaled.

![Radiosynthesis of \[^11^C\]**1**\
RCY = radiochemical yield, EOS = end of synthesis, and RCP = radiochemical purity.](ao-2019-00357c_0003){#sch2}

Although a racemic mixture was employed in the study, the radiotracer distribution obtained with PET is comparable to the autoradiography results. The highest uptake is found in the hippocampus, followed by the cortex, caudate putamen, and thalamus. By far, the lowest binding is observed in the cerebellum. In baseline scans, radioactivity concentration in the brain peaks at 0.7% ID/mL about 5 min into the scan, followed by washout over the following 65 min ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Half maximal concentration in the NR2B-rich regions is reached 30 min post injection (p.i.). When the radiotracer was injected in a low specific activity (1 mg/kg rat), the radioactivity concentration in the brain peaked earlier (1 min) ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)); however, at a higher value (0.9% ID/mL) was presumably due to blocking of peripheral binding sites. In these scans, half maximal concentration is observed at 11 mins, indicating a faster washout consistent with NR2B blocking ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).

![Summed images (15--68 min p.i.) of \[^11^C\]**1** (20.5 MBq) in the rat brain and time activity curves for hippocampus (orange), cerebellum, (red) and caudate putamen (black); average of *n* = 3.](ao-2019-00357c_0001){#fig1}

Pleased with the PET study results that indicate brain uptake, we continued with high-resolution autoradiography experiments for determining both the *K*~d~ of **1** on rat and mouse brain sections and for investigating the binding pattern. Autoradiography would also allow for a series of competition experiments to validate the specificity of binding to NMDA receptors. Unfortunately, the chemical structure of **1** does not contain a fluorine atom, which made necessary the use of carbon-11 (^11^C, *t*~1/2~ = 20 min) as the radionuclide for PET imaging instead of fluorine-18 (^18^F, *t*~1/2~ = 110 min) which due to its longer half-life would have been preferred. Carbon-11 is not suitable for high-resolution autoradiography and the short half-life complicates in vitro experiments. Therefore, we decided to prepare and use ^3^H-labeled 1-(4-chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroiso-quinolin-7-ol, \[^3^H\]**1**, which could be obtained conveniently by catalytic tritiation with an ^3^H~2~ and Crabtree's catalyst. The radioligand \[^3^H\]**1** was labeled with a molar activity of 1.04 GBq/μmol in a radiochemical purity of 99%. \[^3^H\]**1** was used for autoradiography imaging on both rat and mouse brain sections ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Typical image of \[^3^H\]**1** (20 nM \[^3^H\]**1**, 10.5 kBq) on a mouse brain section and displacement curve of \[^3^H\]**1** (4 nM) from the cortex in sagittal rat brain sections by increasing concentrations of (*R*)-**1** and (*S*)-**1** in duplicate. Specific binding correspond to 24% of total binding in the cortex.](ao-2019-00357c_0006){#fig2}

Images obtained with \[^3^H\]**1** were found to show an activity distribution corresponding well with the distribution of NR2B mRNA, albeit in a somewhat more diffuse microdistribution. Furthermore, binding of \[^3^H\]**1** matched the reported distribution obtained using \[^3^H\]**7** or \[^3^H\]Ro 25-9681 with retention in NR2B-rich regions such as the cortex, hippocampus, and to a lesser extent the striatum and thalamus.^[@ref19]^ To rule out likely cross affinities based on structure similarity to opioid receptor antagonists, naloxone (1 μM) was added to \[^3^H\]**1** (20 nM) on mouse brain sections. In the presence of naloxone, no displacement was observed. An addition of 30 μM of a dopamine reuptake inhibitor GBR-12909 (30 μM), described to displace \[^3^H\]**7** from σ and piperidine binding sites by Carter et. al,^[@ref23]^ showed minor displacement, possibly indicating some cross affinity. Furthermore, wiping studies using varying molar activities of \[^3^H\]**1** in the presence of **7** (10 μM) yielded no displacement but instead an increased retention of radioligand (15--40%) at lower concentrations (1--45 nM of **1**) and no effect at higher concentrations (200 nM and 10 μM) compared to control. We believe the reason for the unexpected results is that **7** has a high affinity to other receptors beside NR2B such as σ-receptors. In addition, **7** may influence metabolism of **1**. However, autoradiographic results clearly demonstrated a concentration-dependent displacement of \[^3^H\]**7** by **1** in NR2B-rich regions (cortex and hippocampus) with no displacement in the cerebellum indicating identical binding sites (see above).

Enantiomerically pure **1** (*R* and *S*) was synthesized via crystallisation of **4c** with (*R* )- and (*S*)-*O*-acetylmandelic acids, respectively ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)). Absolute configuration of the enantiomers was established via X-ray diffraction on a crystal of **7a** ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)).^[@ref27]^ The enantiomers were evaluated by incubating \[^3^H\]**1** in the presence of either the *R* or *S* enantiomer of **1** in increasing concentrations (0, 4, 12, 28, 60, 124 nM) on sagittal rat brains ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The enantiomer (*R*)-**1** demonstrated a *K*~i~ of 2 nM, whereas the *S* enantiomer was much less potent. Because of the lack of saturation of \[^3^H\]**1** binding by (*S*)-**1**, curve fits did not converge on a *K*~i~ value.

*B*~max~ was estimated to be around 0.5--1 nmol/mL in the cortex using an Eadie--Hofstedt plot ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf)). At low concentration (\<4 nM) of \[^3^H\]**1**, the molar activity of the radioligand in combination with the low *B*~max~ leads to a poor signal-to-noise ratio obscuring the specific signal. Off-target binding has been a notorious confounder of proposed NMDA (NR2B) ligands described in the literature and next to all commercially available reference compounds. Instead of performing additional blocking studies with structurally very similar ligands to **7**, we subjected **1** to a panel screening of brain targets at a concentration of 10 μM. Compounds showing 50% or higher inhibition of binding to a target in said primary assay were then tested in a concentration-dependent manner to obtain inhibition constants (*K*~i~). [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} shows the outcome of the broad-spectrum screen and *K*~i~ values for critical targets. The assay revealed that **1** does not bind to any of the tested receptors, transporters, and ion channels with high affinity. The notable exception is the mu opioid receptor (MOR) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) for which a *K*~i~ of 66 nM was obtained. However, when coincubating \[^3^H\]**1** with the MOR antagonist naloxone at a concentration of 1 μM, no inhibition of \[^3^H\]**1** binding was observed. In our own experience,^[@ref24]^ a single-figured nanomolar affinity is nanomolar affinity is necessary to image MOR because of its inherent low concentration in the brain.

![Results of the off-target binding experiments from PDSP using **1**.^[@ref24]^ The column diagram on top shows primary test results at a concentration of 10 μM of **1**.](ao-2019-00357c_0005){#fig3}

###### Concentration-Dependent Binding

  receptor   *K*~i~ (μM)   receptor   *K*~i~ (μM)   receptor     *K*~i~ (μM)
  ---------- ------------- ---------- ------------- ------------ -----------------------------------------------
  5-HT1D     2.7           Alpha1D    1.0           H2           1.0
  5-HT2A     0.88          Alpha2A    0.34          MOR          0.066
  5-HT2B     1.7           Alpha2B    0.48          NET          1.4
  5-HT2C     1.4           Alpha2C    0.14          NR2B         0.004 (0.002)[a](#t1fn1){ref-type="table-fn"}
  5-HT3      1.1           D1         0.27          SERT         1.0
  5-HT6      1.9           D4         1.3           Sigma 1 GP   0.37
  5-HT7      1.7           D5         0.2           Sigma 2      0.76
  Alpha1A    2.4           DAT        4.5                         

Value obtained from competitive autoradiography using racemic \[^3^H\]**1** in the presence of increasing concentrations of (*R*)-**1**, *K*~i~ = 0.002 μM (ESI), and *K*~i~ = 0.004 for **1**.

Conclusions {#sec3}
===========

In summary, we successfully synthesized and characterized a selective NR2B radioligand. We believe that a large part of the nonspecific binding seen in AR and PET come from the non-NR2B binding enantiomer ((*S*)-**1**). Reconstructed dynamic PET data using \[^11^C\]**1** show much promise with an NR2B-like distribution, fair brain uptake, and washout within the duration of the PET scan (90 min). By utilizing the PET images coupled with autoradiographic images of the distribution of \[^3^H\]**1**, we were able to assess NR2B binding in vivo and with excellent resolution in vitro. In both cases, binding was confined to NR2B receptor-rich regions with very little visible off-target binding. We identified the (R)-**1** enantiomer as the NR2B-binding ligand.

Experimental Section {#sec4}
====================

General Experimental Methods {#sec4.1}
----------------------------

Reactants, reagents, and solvents used herein were procured from Sigma-Aldrich, Tocris Biosciences, or Perkin-Elmer in the highest quality, unless otherwise specified. Nuclear magnetic resonance spectra were recorded on a Bruker AVII 400 NMR instrument (Bruker ASX Nordic AB). Chemical shifts (δ) for proton (400 MHz) and ^13^C (100 MHz) resonances are reported in parts per million (ppm), relative to the solvent signal (CDCl~3~ δ = 7.226 ppm), and downfield from the expected tetramethylsilane signal (TMS, δ = 0 ppm). Mass spectrometry was conducted on a maXis II ETD from Bruker Daltonics time of flight instrument with a flight tube of 3 m using electron spray ionization in a positive mode. Calculated exact mass is reported for the positively charged ion. The samples were prepared in a solution from methanol or acetonitrile in 1 mg/mL concentration. TLC was conducted on Silica gel 60 F~254~**-**coated aluminum TLC plates (Supelco, USA). Optical rotation was measured on a polarimeter (Perkin Elmer model 341) at 589.6 nM and 20 °C in methanol (MeOH) using a 10 cm-long tube with 1 mL capacity. Values are averaged from at least three measurements using the same sample. Autoradiography data was evaluated using AIDA imaging analyzer software version 5.1 from Elysia-Raytest and GraphPad Prism 6. Brain tissues were cut using a Thermo-Fischer Scientific Cryo Star NX-70 cryostat. LSC was done using a HIDEX 300 SL, and autoradiographic screens were read using a Dürr CR35 Bio Plus image plate scanner. Compounds used for biological characterization were of equal or greater purity than 95%.

### ^11^C-Methylation {#sec4.1.1}

Carbon-11 was produced using a Siemens Eclipse cyclotron in the form of \[^11^C\]CO~2~. The labeling process was automated on a Synthra MeI plus research synthesis module. ^11^C-Methylation of 1-(4-chlorophenethyl)-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-7-ol (0.4 mg, 1.3 μmol) was methylated using \[^11^C\]CH~3~I, using captive solvent radiosynthesis in DMF (50 μL) via heating at 40 °C for 1 min. Purification of the crude product was performed on a Macherey-Nagel VarioPrep NUCLEODUR C18 Pyramid, 5 μm, 250 mm × 10 mm HPLC column, using a flow of 5.5 mL/min and MeCN--0.1 M HCO~2~NH~4~ buffer, 44:56 as mobile phase. The product fraction containing \[^11^C\]**1** was collected after a retention time of 5.6--6.5 min.

### General Pictet--Spengler Cyclization Reaction {#sec4.1.2}

To phenethylamine (1.3 mmol) in Et~2~O (1 mL) was added cinnamic aldehyde (200 mg, 1.0 mmol). Solvent was removed under reduced pressure at 30 mbar at 40 °C. TFA (2.0 mL) was added. The reaction mixture was purged with argon and heated in a microwave reactor (120--130 °C for 15--60 min). The reaction mixture was basified via addition of aqueous ammonia (veratrol) or NaHCO~3~ (guaiacol) and diluted with EtOAc. The phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine, dried over sodium sulphate, and evaporated to dryness under reduced pressure. Purification via flash column chromatography using 2--8% MeOH in DCM yielded the target compound.

### General Hydrogenation {#sec4.1.3}

To Raney nickel in MeOH (5 mL) was added a magnetic stirrer bar, and the slurry was vigorously stirred. The solvent was withdrawn, and the washing step was repeated two additional times. Alkene dissolved in MeOH/AcOH (4:1, 40 mL/mmol) was added and H~2~ fitted. The reaction was left over night. The catalyst was filtered off, and solvents were removed under reduced pressure. The reaction mixture was basified with aqueous ammonia (for veratrole derivatives) or pH adjusted to 8--9 with saturated NaHCO~3~ (for guaiacol derivatives) and extracted with EtOAc. The combined organic phases were washed with brine and dried over sodium sulphate. The solvent was removed under reduced pressure, and the crude was purified via flash column chromatography affording the target compounds.

### (*E*)-6,7-Dimethoxy-1-(4-nitrostyryl)-1,2,3,4-tetrahydroisoquinoline (**4c**) {#sec4.1.4}

#### Synthesized in Accordance to General Pictet--Spengler Cyclization Reaction {#sec4.1.4.1}

Purification via flash column chromatography using 5.5% MeOH in DCM yielded the target compound as brown solids in 83% (563 mg, 1.65 mmol). ^1^H NMR (400 MHz, Chloroform-*d*) δ 8.21--8.14 (m, 2H), 7.55--7.49 (m, 2H), 6.64 (d, *J* = 15.7 Hz, 1H), 6.64 (s, 1H), 6.56 (s, 1H), 6.53 (q, *J* = 15.7, 7.5 Hz), 4.64 (d, *J* = 7.5 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.26 (dt, *J* = 11.7, 5.6 Hz, 1H), 3.08 (ddd, *J* = 12.2, 7.3, 4.9 Hz, 1H), 2.90--2.69 (broad s, 2H). ^13^C NMR (101 MHz, CDCl~3~) δ 148.2, 147.5, 147.1, 143.5, 137.4, 130.1, 128.0, 127.4, 127.1, 124.2, 112.2, 110.5, 58.9, 56.2, 56.1, 41.4, 29.3. HR-ESIMS: *m*/*z* 341.1498 \[M + H\]^+^ (C~19~H~21~N~2~O~4~^+^, calcd 314.1496).

### Chiral Resolution of (*R*)- and (*S*)-**1** {#sec4.1.5}

Chiral resolution of (*R*)- and (*S*)-**1** was achieved via cocrystallization as diastereomeric salts with *(R*) and (*S*)-*O*-acetylmandelic acids from acetonitrile, respectively.

### (*R*,*E*)-6,7-Dimethoxy-1-(4-nitrostyryl)-1,2,3,4-tetrahydroisoquinoline (**4c**) {#sec4.1.6}

To **4c** (1.33 g, 3.90 mmol) were added (*R*)-(−)-*O*-acetylmandelic acid (794 mg, 4.09 mmol) and acetonitrile (56 mL). The reaction mixture was heated to reflux until clear. The solution was kept in room temperature for two days. The solids were filtered and washed with cold acetonitrile, affording pale yellow solids in 24% (493 mg, 0.92 mmol). The supernatant was evaporated to dryness and submitted to one more recrystallization using a minimum amount of acetonitrile. 36% yield (750 mg (1,40 mmol). ^1^H NMR (400 MHz, Chloroform-*d*) δ 9.41 (broad s, 2H), 8.14--8.06 (m, 2H), 7.46--7.39 (m, 2H), 7.25--7.13 (m, 6H), 6.59 (s, 1H) 6.54 (d, *J* = 15.8 Hz, 2H), 6.39 (s, 1H), 6.35 (dd, 7.7, 15.8 Hz, 2H), 5.56 (s, 1H), 4.79 (d, *J* = 7.6 Hz, 1H), 3.89 (s, 3H), 3.78 (s, 3H), 3.11--3.02 (m, 1H), 2.98--2.80 (m, 2H), 2.75--2.65 (m, 1H), 2.08 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 174.28, 170.86, 149.10, 148.18, 147.52, 142.19, 136.65, 135.10, 130.59, 128.40, 128.28, 127.88, 127.51, 124.80, 124.00, 122.71, 111.54, 110.21, 77.23, 56.69, 56.21, 56.11, 39.39, 25.43, 21.25. HR-ESIMS: *m*/*z* 341.1495 \[M + H\]^+^ (C~19~H~21~N~2~O~4~^+^, calcd 341.1496). −0.63 (*c* 0.23, MeOH). The absolute configuration was determined using X-ray diffraction on the corresponding *p*-toluenesulfonyl amide.

### (*E*)-1-(4-Chlorostyryl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (**4g**) {#sec4.1.7}

#### Synthesized in Accordance to General Pictet--Spengler Cyclization Reaction {#sec4.1.7.1}

Purification via flash column chromatography using 8% MeOH in DCM yielded the target compound as light brown solids in 8% (14 mg, 0.044 mmol). ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.46 (d, *J* = 8.5 Hz, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 6.73 (s, 1H), 6.65 (d, *J* = 15.8 Hz, 1H), 6.59 (s, 1H), 6.34 (dd, *J* = 15.8, 8.1 Hz, 1H), 4.57 (d, *J* = 8.1 Hz, 1H), 3.86 (s, 3H), 3.28 (dt, *J* = 11.3, 5.3 Hz, 1H), 3.05 (ddd, *J* = 12.4, 8.3, 4.9 Hz, 1H), 2.97--2.84 (m, 1H), 2.78 (dt, *J* = 16.2, 5.2 Hz, 1H). ^13^C NMR (101 MHz, MeOD) δ 148.2, 145.8, 137.0, 134.3, 133.0, 132.9, 129.7, 129.4, 129.0, 126.8, 115.0, 113.1, 60.0, 56.4, 42.3, 29.1. HR-ESIMS: *m*/*z* 316.1099 \[M + H\]^+^ (C~18~H~19~ClNO~2~^+^, calcd 316.1099).

### 6-Methoxy-1-phenethyl-1,2,3,4-tetrahydroisoquinolin-7-ol (**4h**) {#sec4.1.8}

#### Synthesized in Accordance to General Hydrogenation {#sec4.1.8.1}

Purification via flash column chromatography yielded a mix of proto and chloro analogs as yellow solids (18 mg). The crude was further purified via HPLC (HS F5 column; 25 mm × 10 mm) 5 mL/min using 70% MeCN and 30% H~2~O containing 0.1% TFA. Bulk solvents were removed under reduced pressure and pH adjusted to 8--9 using saturated NaHCO~3~. The aqueous phase was extracted with EtOAc. The combined organic phases were dried over sodium sulphate, and solvents were removed under reduced pressure obtaining the target compound in 43% as pale yellow solids (12 mg, 38 μmol) (eluting at 13.00--18.10 min). ^1^H NMR (400 MHz, MeOH-*d*~4~) δ 7.32--7.21 (m, 4H), 6.66 (s, 1H), 6.60 (s, 1H), 4.00--3.93 (m, 1H), 3.82 (s, 3H), 3.31--3.23 (m, 1H), 3.04--2.94 (m, 1H), 2.89--2.64 (m, 4H), 2.18--1.96 (m, 2H). ^13^C NMR (101 MHz, MeOD) δ 147.9, 146.0, 142.1, 132.7, 131.0, 130.6, 129.5, 126.5, 113.8, 113.0, 56.4, 55.9, 41.8, 38.8, 32.4, 29.0. HR-ESIMS: *m*/*z* 318.1256 \[M + H\]^+^ (C~18~H~21~ClNO~2~^+^, calcd 318.1255).

### (*R*,*E*)-6,7-Dimethoxy-2-methyl-1-(4-nitrostyryl)-1,2,3,4-tetrahydroisoquinoline (**5c**) {#sec4.1.9}

To **4c** (759 mg, 2.23 mmol) in dichloroethane (22 mL) was added 37% formaldehyde (1.8 mL, 22 mmol) and left to stir for 1 h. Na(OAc)~3~BH (709 mg, 3.35 mmol) was added in one portion, and the reaction mixture was left to stir over night. The reaction mixture was diluted with water and aqueous ammonia, the phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine and dried over sodium sulphate. Flash column purification yielded the target compound in 96% yield (758 mg, 2.14 mmol) as fluffy yellow solids. ^1^H NMR (400 MHz, Chloroform-*d*) δ 8.22--8.14 (m, 2H), 7.58--7.49 (m, 2H), 6.68 (d, *J* = 15.9 Hz, 1H), 6.63 (s, 1H), 6.54 (s, 1H), 6.35 (dd, *J* = 15.9, 8.7 Hz, 1H), 3.91 (d, *J* = 8.6 Hz, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 3.08 (ddd, *J* = 11.2, 5.3, 4.0 Hz, 1H), 3.05--2.95 (m, 1H), 2.74 (dt, *J* = 16.0, 4.1 Hz, 1H), 2.60 (ddd, *J* = 11.2, 9.4, 4.2 Hz, 1H), 2.47 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~) δ 148.00, 147.30, 146.98, 143.15, 136.92, 130.83, 127.16, 126.93, 126.70, 124.06, 111.51, 110.84, 68.05, 56.06, 55.88, 50.92, 44.13, 28.64. HR-ESIMS: *m*/*z* 355.1652 \[M + H\]^+^ (C~20~H~23~N~2~O~4~^+^, calcd 355.1652). \[α\]~D~^20^ + 0.25 (*c* 0.45, MeOH).

### (*R*)-1-(4-Chlorophenethyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline (**6b**) {#sec4.1.10}

At 0 °C to **6e** (23 mg, 0.071 mmol) in 1.6 M aqueous HCl (6 mL/mmol) was added 1 M aqueous sodium nitrite (0.085 mL, 0.085 mmol). The pale yellow reaction mixture was stirred for 30 min. A concentration of 0.5 M CuCl in 37% aqueous HCl (11 mg, 0.11 mmol in 0.4 mL) was added dropwise, and the reaction mixture was left to stir for 30 min. The reaction mixture was allowed to reach room temperature and kept until the reaction mixture was pale blue. The reaction mixture was basified using 28% aqueous NH~3~ and extracted with EtOAc. The combined organic phases were dried over sodium sulphate and evaporated to dryness under reduced pressure.

Flash column purification yielded the target compound in 38% yield (10 mg, 0.0269 mmol) as yellow oil. Analytical information was in agreement to racemic compound reported by Richter et al.^[@ref25]^ −0.11 (*c* 0.32, MeOH).

### (*R*)-4-(2-(6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)ethyl)aniline (**6e**) {#sec4.1.11}

#### Synthesized in Accordance to General Hydrogenation {#sec4.1.11.1}

Purification via flash column purification yielded the target compound in 56% yield (398 mg, 1.20 mmol) as yellow oil. ^1^H NMR (400 MHz, Chloroform-*d*) δ 7.00--6.95 (m, 2H), 6.64--6.59 (m, 2H), 6.57 (s, 1H), 6.54 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.53 (d, *J* = 53.2 Hz, 1H), 3.42 (t, *J* = 5.5 Hz, 2H), 3.21--3.10 (m, 1H), 2.83--2.60 (m, 4H), 2.53--2.43 (m, 4H), 2.08--1.95 (m, 2H). ^13^C NMR (101 MHz, CDCl~3~) δ 147.40, 147.36, 144.21, 132.94, 130.04, 129.29, 126.67, 115.36, 111.45, 110.30, 62.78, 56.12, 55.92, 48.14, 42.69, 37.22, 30.90, 25.47. HR-ESIMS: *m/z* 327.2067 \[M + H\]^+^ (C~20~H~27~N~2~O~2~^+^, calcd 327.2067). \[α\]~D~^20^ -- 0.09 (*c* 2.4, MeOH).

### (*R*)-1-(4-Chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol (**1**) {#sec4.1.12}

To **6b** (104 mg, 0.3 mmol) in DMF (1.5 mL) were added a suspension of ethanethiol (54 μL, 0.75 mmol) and sodium hydride (30 mg, 0.75 mmol) in DMF (1 mL). The reaction mixture was thoroughly purged with argon and heated to 150 °C for 30 min. The reaction mixture was diluted with DCM and washed with water and brine. The organic phase was dried over sodium sulphate, and solvents were removed under reduced pressure. Repeated chromatography using 7.5% MeOH and 0.6% EtOH in CHCl~3~ yielded.

### (*R*)-1-(4-Chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol {#sec4.1.13}

(*R*)-1-(4-chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol was in 9% as yellow oil (9 mg, 0.027 mmol). ^1^H NMR (400 MHz, Chloroform-*d*) δ 7.25--7.20 (m, 2H), 7.15--7.09 (m, 2H), 6.65 (s, 1H), 6.47 (s, 1H), 5.57 (s, 1H), 3.83 (s, 3H), 3.46 (t, *J* = 5.7 Hz, 1H), 3.22--3.13 (m, 1H), 2.82--2.66 (m, 4H), 2.58 (ddd, *J* = 14.3, 10.0, 5.1 Hz, 1H), 2.49 (s, 3H), 2.16--1.92 (m, 2H). ^13^C NMR (101 MHz, CDCl~3~) δ 145.3, 144.2, 141.2, 131.5, 130.0, 128.6, 128.5, 128.5, 127.0, 125.8, 114.4, 109.4, 62.9, 56.2, 47.8, 42.5, 37.0, 31.1, 24.9. HR-ESIMS: *m/z* 332.1412 \[M + H\]^+^ (C~19~H~23~ClNO~2~^+^, calcd 332.1412) \[α\]~D~^20^ + 0.03 (c = 1.44 MeOH). \>95% HPLC UV purity 230 nm. ^1^H-NMR reveal \<5% of the constitutional isomer.

### (*S*)-1-(4-Chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol (**1**) {#sec4.1.14}

(*S*)-1-(4-Chlorophenethyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol (**1**) was synthesized analogously to the *R* enantiomer.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b00357](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b00357).Supplemental procedures, protocols, and analytical data ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b00357/suppl_file/ao9b00357_si_001.pdf))
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